Commercial

• Commercial

Novo’s CEO champions “record-breaking start” for Wegovy pill in US market

pharminent May 8, 2026

• Commercial

Novo hikes guidance on Wegovy pill’s fast sales start

pharminent May 6, 2026

• Commercial

Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales

pharminent May 6, 2026

• Commercial

Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

pharminent May 5, 2026

• Commercial

Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq

pharminent May 4, 2026

• Commercial

Novo Nordisk to launch Ozempic for type 2 diabetes in US

pharminent May 4, 2026

• Commercial

Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening

pharminent May 1, 2026

• Commercial

Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

pharminent April 30, 2026

• Commercial

Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth

pharminent April 30, 2026

• Commercial

Regeneron Q1 2026 net income falls 10% to $727m

pharminent April 30, 2026

• Commercial

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

pharminent April 29, 2026

• Commercial

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

pharminent April 29, 2026

• Commercial

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

pharminent April 29, 2026

• Commercial

Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

pharminent April 29, 2026

• Commercial

Pfizer deals extend patent life for a top-selling rare disease drug

pharminent April 28, 2026

• Commercial

Novartis shares fall as Entresto sales weaken

pharminent April 28, 2026

• Commercial

Lilly falls on slower start for Foundayo versus Wegovy

pharminent April 27, 2026

• Commercial

Daiichi Sankyo shares slip after delaying annual earnings report

pharminent April 24, 2026

• Commercial

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

pharminent April 24, 2026

• Commercial

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

pharminent April 23, 2026

• Commercial

Sanofi posts upbeat sales as R&D pressure builds

pharminent April 23, 2026

• Commercial

Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

pharminent April 23, 2026

• Commercial

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground

pharminent April 21, 2026

• Commercial

The Omnichannel Gap: Building the CRM of the Future for Patient Services

pharminent April 20, 2026

• Commercial

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

pharminent April 17, 2026

• Commercial

Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch

pharminent April 17, 2026

• Commercial

Revolution doubles stock offering target to $2B following pancreatic cancer win

pharminent April 16, 2026

• Commercial

J&J sets the tone for Q1 earnings with strong oncology growth

pharminent April 15, 2026

• Commercial

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

pharminent April 14, 2026

• Commercial

With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026

pharminent April 14, 2026

• Commercial

Alamar, Hemab, Kailera, and Seaport advance IPOs

pharminent April 14, 2026

• Commercial

With oral obesity race underway, all eyes are on Lilly’s Foundayo launch

pharminent April 10, 2026

• Commercial

Senju launches first-in-class dry eye disease drug in Japan

pharminent April 10, 2026

• Commercial

Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

pharminent April 9, 2026

• Commercial

Activist investor renews its criticism of Novavax

pharminent April 8, 2026

• Commercial

Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences

pharminent April 2, 2026

• Commercial

Novo hits back at rivals with cut-price Wegovy subscriptions

pharminent March 31, 2026

• Commercial

Novartis, Takeda Add Hundreds to Workforce Chopping Block

pharminent March 31, 2026

• Commercial

The Rare Journey Needs a Special Pharmacy Partner

pharminent March 27, 2026